Moreover, in two rat MS models, anti-CD20 therapy reduced the number of MHC-II-positive microglia and decreased the binding of the TSPO-radioligand (125I)DPA-713, indicating decreased microgliosis [71]. The gene discussed is TSPO; the disease is myeloid sarcoma.